Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs BLLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRAL Captures Overall Composite Edge (54.5 HOLD vs 45.8 HOLD), While BLLN Leads 5–1 on Growth & Valuation Pillars

GRAL Overall Winner 6-Pillar Tally: GRAL 1 – 5 BLLN Matrix Metrics: GRAL 5 – 5 BLLN

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over BillionToOne, Inc. (BLLN) on higher Unified Composite conviction (54.5/100 HOLD vs. 45.8/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while BLLN wins 5–1 across the 6-pillar growth and valuation breakdown. GRAL trades at $105.60 (1.1x Forward P/E, -332.0% operating margin) versus BLLN at $96.31 (61.3x Forward P/E, 10.2% operating margin).

  • Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. BLLN 45.8/100 HOLD) and 3.09β · 99% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile BLLN is in a Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs BLLN
GRAL NASDAQ Head-to-Head Winner
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
BLLN US Equity
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93

6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 5 BLLN)

Columns: Metric · GRAL · BLLN
1. Valuation Multiples GRAL
Forward P/E 1.1x 61.3x
Trailing P/E 1.1x 114.3x
PEG Ratio N/M N/M
EV / Revenue 31.6x 10.5x
2. Growth & Scale BLLN
Revenue Growth (YoY) +3.7% +47.2%
Earnings Growth (YoY) +0.0% +220.0%
TTM Revenue (USD) $167M $437M
Market Cap $5.2B $5.0B
3. Profitability & Quality BLLN
Gross Margin 46.7% 71.4%
Operating Margin -332.0% 10.2%
Net Profit Margin -243.8% 10.5%
Return on Equity (ROE) -17.3% 13.2%
4. Balance Sheet & Cash Flow BLLN
Cash Generation (TTM) -$312M $34M
Cash Flow Margin N/A 7.8%
Net Cash / Leverage $57M Net Debt (0.03x D/E) $421M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLLN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 93.0% (53rd %ile) 113.8% (26th %ile)
Put/Call OI Skew 0.81x (Call-Skewed) 1.21x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat BLLN
OpEx & R&D Intensity N/A 61.2% of Rev ($267M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (5) vs BLLN (5)
Institutional Metric GRAL BLLN Criterion Row Edge
Market Capitalization
Scale
$5.2B $5.0B Larger Scale GRAL
Trailing P/E Ratio
Valuation
1.1x 114.3x Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x 61.3x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +47.2% Higher Growth BLLN
Operating Margin (TTM)
Profitability
-332.0% 10.2% Higher Margin BLLN
Net Profit Margin
Profitability
-243.8% 10.5% Higher Margin BLLN
Return on Equity (ROE)
Capital Efficiency
-17.3% 13.2% Higher ROE BLLN
52-Week Range Position
Momentum
51% ($42–$166) 39% ($62–$150) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 1.44β · 42% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $437M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 71.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev N/M PEG · 10.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) $34M ($421M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLLN +8.52 pp
GRAL: -10.36% · BLLN: -1.84%
3M Horizon GRAL +48.4 pp
GRAL: +50.96% · BLLN: +2.56%
6M Horizon GRAL +60.47 pp
GRAL: +77.03% · BLLN: +16.56%
1Y Horizon GRAL +19.37 pp
GRAL: +26.92% · BLLN: +7.55%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GRAL Revenue BLLN Revenue GRAL Op. Margin BLLN Op. Margin Margin Leader
FY2023 $90M $70M -1627.6% -96.9% BLLN
FY2024 $130M $150M -1743.0% -30.9% BLLN
FY2025 $150M $310M -382.0% 5.3% BLLN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs BLLN Key Questions & Quantitative Answers

As of Nov 16, 2026, GRAIL, Inc. (GRAL) captures the overall head-to-head institutional edge over BillionToOne, Inc. (BLLN) on higher Unified Composite conviction (54.5/100 HOLD vs. 45.8/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while BLLN wins 5–1 across the 6-pillar growth and valuation breakdown. GRAL trades at $105.60 (1.1x Forward P/E, -332.0% operating margin) versus BLLN at $96.31 (61.3x Forward P/E, 10.2% operating margin). Growth vs. Quality Trade-Off: GRAL earns the overall head-to-head edge with a stronger Unified Composite Score (54.5/100 HOLD vs. BLLN 45.8/100 HOLD) and 3.09β · 99% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile BLLN is in a Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with BLLN at +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), GRAL cumulative revenue shifted +66.7% while BLLN shifted +342.9%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 61.2% of Rev ($267M) (0 disclosures) for BLLN.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus BLLN (13.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.